Skip to main content
. 2013 Nov 12;25(1):32–40. doi: 10.1093/annonc/mdt384

Table1.

Active PARP is under development

PARPi Treatment Cancer types Phase
Olaparib (AstraZeneca) -Monotherapy
-Combinations with cytotoxic chemotherapy
-Combinations with targeted agents
-Combinations with RT		 BRCA1/2MUT+ associated
BrCa/OvCa,
BRCA-like tumors,
Advanced hematologic malignancies and solid tumors,
Maintenance study following remission in platinum sensitive OvCa (pending)		 I/II/III
Veliparib (Abbott) -Monotherapy
-Combinations with cytotoxic chemotherapy
-Combinations with targeted agents
-Combinations with RT		 BRCA1/2MUT+ associated BrCa/OvCa,
BRCA-like tumors,
Advanced hematologic malignancies and solid tumors		 I/II
BMN 673 (BioMarin) - Monotherapy Advanced hematologic malignancies and solid tumors I
Rucaparib (Clovis) -Monotherapy
-Combinations (carboplatin)		 Advanced solid tumors,
Recurrent OvCa,
BRCA1/2MUT+ associated BrCa/OvCa		 I/II
CEP-9722 (Cephalon) -Monotherapy
-Combinations with cytotoxic chemotherapy		 Advanced solid tumors I
Niraparib (MK-4827) (TesaroBio) -Monotherapy
-Combinations (temazolomide)		 Advanced hematologic malignancies and solid tumors,
BRCA1/2MUT+ associated and HER2 negative BrCa,
Maintenance study following remission in platinum sensitive OvCa (pending)		 I/III

*OvCa, ovarian cancer; BrCa, breast cancer; RT, radiation therapy.